Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.15425 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Valentin Skryabin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Ru…. Hauptthemen laut MEDLINE: MicroRNAs, Precision Medicine, Pharmacogenomic Testing, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Acute alcoholic hallucinosis (ICD-10 F10.52) necessitates urgent antipsychotic treatment but carries high risks of adverse drug reactions (ADRs). While pharmacogenetic clinical decision support systems (CDSS) show promise, their utility is limited by static genotyping and incomplete biomarker integration.
Purpose
This study aimed to develop and validate a multi-omics framework integrating pharmacogenetic testing, CYP phenotyping, and microRNA biomarkers to personalize antipsychotic therapy and improve outcomes in acute alcoholic hallucinosis. Material and methods: In this three-arm study, 300 Russian inpatients with acute alcoholic hallucinosis underwent: 1) Randomized pharmacogenetic-guided vs. standard therapy (n = 100); 2) CYP2D6/CYP3A4 phenotyping via urinary pinoline/cortisol ratios (n = 100); and 3) microRNA quantification (miR-27b, miR-370-3p; n = 100). Efficacy (PANSS) and safety (UKU) were assessed over 6 days.
Results
Pharmacogenetic guidance significantly reduced ADRs (UKU day 6: 5.0 [3.0 − 8.0] vs. 12.0 [10.0 − 16.0], p < 0.01) with comparable efficacy (PANSS≈1.0). Phenotyping identified 28% CYP2D6 poor metabolizers (vs. 15% by genotyping), exhibiting 40% higher haloperidol levels (r = 0.72, p < 0.001). Baseline miR-27b inversely correlated with day-3 PANSS (r = − 0.54, p < 0.001), while miR-370-3p predicted poorer day-6 response (ΔPANSS r = 0.48, p < 0.001) and higher UKU scores (r = 0.52, p < 0.001). Integrating microRNAs with phenotyping improved ADR prediction accuracy by 22% versus single modalities.
Conclusion
A multi-omics approach synergistically optimizes antipsychotic therapy by addressing genotyping limitations through dynamic phenotyping and microRNA-based prognostication, significantly enhancing safety in this high-risk population. Psychopharmacology Bulletin. 2026;56(1):82–91.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Masyakin, PhD, MD, director, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Pozdniakov, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Shatokhin, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Sokolova, researcher, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Ivanchenko, laboratory research assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
Zitieren
APA
Skryabin, V., Masyakin, A., Pozdniakov, S., Shatokhin, I., Sokolova, S., Ivanchenko, V., & Makartseva, P. (2026). Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15425
Vancouver
Skryabin V, Masyakin A, Pozdniakov S, Shatokhin I, Sokolova S, Ivanchenko V, et al. Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15425
BibTeX
@article{Skryabin2026,
author = {Skryabin, Valentin and Masyakin, Anton and Pozdniakov, Sergei and Shatokhin, Igor and Sokolova, Svetlana and Ivanchenko, Valentina and Makartseva, Polina},
title = {Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.15425}
}
EUVIMED